Table 4.
Anthracycline and Taxane
Based (N = 57) |
Taxane
Based (N = 18) |
Anthracycline
Based (N = 7) |
||||
pCR (N = 16) |
Residual
Tumor (N = 41) |
pCR (N = 6) |
Residual
Tumor (N = 12) |
pCR (N = 0) |
Residual
Tumor (N = 7) |
|
MTVcsc < 1.75 cm3 | 16 | 14 | 6 | 5 | 0 | 2 |
MTVcsc > 1.75 cm3 | 0 | 27 | 0 | 7 | 0 | 5 |
Prediction accuracy | 75% (43/57) | 72% (13/18) | 71% (5/7) | |||
with Anti-HER2
NAC (N = 31) |
without Anti-HER2
NAC (N = 26) |
|||||
pCR (N = 12) |
Residual
Tumor (N = 19) |
pCR (N = 4) |
Residual
Tumor (N = 22) |
|||
MTVcsc < 1.75 cm3 | 12 | 5 | 4 | 13 | ||
MTVcsc > 1.75 cm3 | 0 | 14 | 0 | 9 | ||
Prediction accuracy | 84% (26/31) | 50% (13/26) |